Atlas Trials

Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM

Clinical trial NCT03481556 · TERMINATED

Trial details

NCT number
NCT03481556
Sponsor
Oncopeptides AB
Status
TERMINATED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2018-04-12
Primary completion
2022-02-02
Enrollment
56

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.